| Study Details | To Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy |
| Protocol Number | TAK-079 |
| Phase | Ib |
| Therapeutic Area | Nephrology |
| Subject Types | With Medical Condition |
| Indication | Primary IgA Nephropathy |
| Principal Investigator | A/Prof Jimmy Teo Boon Wee |
| Investigator Product / Device | Mezagitamab (TAK-079) |
| Sponsor | Takeda Development Center Americas, Inc |
